Pyrilutamide
Clinical data | |
---|---|
Other names | KX-826 |
Routes of administration | Topical |
Drug class | Nonsteroidal antiandrogen |
ATC code |
|
Identifiers | |
| |
Chemical and physical data | |
JSmol) | |
| |
|
Pyrilutamide (developmental code name KX-826) is a
androgenic alopecia (androgen-dependent scalp hair loss)[1][2][3] As of October 2022, it is in phase 3 clinical trials for androgenic alopecia and phase 2 trials for acne.[2]
Development
The primary endpoint is the change from baseline in non-vellus target area hair count (TAHC) at the end of week 24. The drug will be dosed at 10 mg (0.5% BID) per patient per day in the trial.[4]
Adverse effects
Pyrilutamide is generally well-tolerated. The most common adverse event is contact dermatitis.[5]
Pharmacology
Pharmacodynamics
Pyrilutamide binds to the androgen receptor with a very high affinity with an IC50 of 0.28 nM. [3] Reference drug bicalutamide had an IC50 of 3.1 nM. [3]
References
- PMID 36169916.
- ^ a b "Pyrilutamide - Suzhou Kintor Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG.
- ^ a b c CA patent 2829322, Tong Y, "Substituted Thioimidazolidinone Androgen Receptor Antagonists and Uses Thereof", published 2012-03-08, issued 2017-01-10, assigned to Suzhou Kintor Pharmaceuticals, Inc
- ^ "Kintor Pharma Announces the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Androgenetic Alopecia Was Met".
- ^ "Kintor Pharmaceutical (9939 HK) Specializing in AR-related innovative therapies" (PDF).